Needham analyst Chad Messer maintained a Buy rating on Akebia Therapeutics (AKBA) today and set a price target of $10.00.
The post Akebia Therapeutics (AKBA) Receives a Buy from Needham appeared first on Smarter Analyst.
Needham analyst Chad Messer maintained a Buy rating on Akebia Therapeutics (...

https://www.smarteranalyst.com/new-blurbs/akebia-therapeutics-akba-receives-a-buy-from-needham-4/

#SmarterAnalyst